CYP1 enzymes catalyse the generation highly mutagenic compounds via activation of procarcinogens (such as polycyclic aromatic hydrocarbonsand and aromatic amines) that are present in combustion products. They can also deactivate many anticancer agents [4].

Because the activity of CYP1s is associated with cancer, selective pharmacological inhibitors have oncology potential.

1. Divanovic S, Dalli J, Jorge-Nebert LF, Flick LM, Gálvez-Peralta M, Boespflug ND, Stankiewicz TE, Fitzgerald JM, Somarathna M, Karp CL et al.. (2013) Contributions of the three CYP1 monooxygenases to pro-inflammatory and inflammation-resolution lipid mediator pathways. J. Immunol., 191 (6): 3347-57. [PMID:23956430]

2. Dutour R, Poirier D. (2017) Inhibitors of cytochrome P450 (CYP) 1B1. Eur J Med Chem, 135: 296-306. [PMID:28458135]

3. Liu J, Taylor SF, Dupart PS, Arnold CL, Sridhar J, Jiang Q, Wang Y, Skripnikova EV, Zhao M, Foroozesh M. (2013) Pyranoflavones: a group of small-molecule probes for exploring the active site cavities of cytochrome P450 enzymes 1A1, 1A2, and 1B1. J. Med. Chem., 56 (10): 4082-92. [PMID:23600958]

4. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. (2001) Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol., 62 (2): 207-12. [PMID:11389879]

5. Sridhar J, Goyal N, Liu J, Foroozesh M. (2017) Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date. Molecules, 22 (7). [PMID:28698457]

6. Stoilov I, Akarsu AN, Sarfarazi M. (1997) Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet., 6 (4): 641-7. [PMID:9097971]